On August 15, 2022, Rocgene (Beijing) Technology Co., Ltd. (abbreviation: Rocgene) and China Bio Shanghai Jienuo Biotechnology Co., Ltd. (abbreviation: Zhongsheng Jienuo) formally reached a strategic cooperation, and both parties will give full play to their respective technologies Reserves and advantages, to jointly promote the clinical application of automated, intelligent and multiplex fluorescent PCR technology in the fields of tumor methylation early screening, multi-target pathogen detection and other fields, provide users with more abundant and complete product solutions, and carry out long-term in-depth cooperation .
As the first step of cooperation, the two parties will combine the newly obtained first-certificate product of domestic cervical cancer HPV methylation shunt--"human ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671 gene methylation Detection Kit (Fluorescence PCR Method)" (referred to as "Gong Anli®"), to create an overall solution for tumor methylation early screening and detection including "instruments + reagents + intelligent software", making tumor molecular diagnosis more Efficient, simple and accessible.
Mr. Guo Qiuzhen
Founder and CEO of Rocgene
"Zhongsheng Jienuo can become the first batch of enterprises to obtain the medical device registration certificate of the new crown nucleic acid detection kit and Gong Anli® - the first certificate of methylation and shunting of cervical cancer HPV primary screening in China, which fully reflects the company's role in tumor development. and the technical advantages and innovation capabilities in the field of nucleic acid detection of multiple pathogens. I am very honored to cooperate with such an excellent team as Zhongsheng Jienuo. I hope that both parties will work together to launch better products and services through mutual empowerment and complementary advantages. to promote the development of China's molecular diagnostics industry."
Mr. Xia Xiaokai
General Manager of Zhongsheng Jienuo
"As a core domestic supplier of PCR technology and products, Rocgene's Archimed series fluorescence PCR instrument can achieve a large-scale market launch of its products in a short period of time and gain a good reputation from users, which is inseparable from its deep technical accumulation and a strong industrialization system. Based on the close cooperation that has been carried out during the epidemic period, both parties feel that the two companies share the same point of culture with rigorous pragmatism, customer orientation and technological innovation. Through further strategic cooperation, they will complement each other in technology and products. It is believed that both parties will actively To help the rapid development of the domestic IVD industry.”
During the epidemic, Rocgene and Zhongsheng Jienuo, relying on their respective advantages in fluorescence PCR instruments, nucleic acid detection reagents, makeshift laboratories and detection services, worked together on the front line of the fight against the epidemic. Through cooperation, they have successively served large nucleic acid testing bases in Shanghai, Beijing, Macau, Lanzhou and other regions, contributing to the prevention and control of the epidemic in various places, and accumulated rich experience in cooperation.
About Zhongsheng Jienuo
Shanghai Jienuo Biotechnology Co., Ltd. is affiliated to China National Pharmaceutical Group Co., Ltd. China Biotechnology Co., Ltd. It is a unified operation platform for medical diagnosis under China Biotechnology. Zhongsheng Jienuo is the first batch of successfully developed new coronavirus nucleic acid detection kits, and the first batch to obtain the new coronavirus nucleic acid detection kit medical device registration certificate issued by the State Drug Administration.
Zhongsheng Jienuo is positioned as a global leading technology industrialization transformation platform in the field of IVD. Its products focus on multiple detection of infectious disease pathogens and molecular diagnosis of tumors, mainly including cervical cancer methylation detection kits, respiratory, encephalitis/meningitis, Single-tube multiple pathogen nucleic acid detection kits for intestinal, central nervous system, prenatal and postnatal reproductive tract infections, etc., serve major clinical hospitals, disease prevention and control centers, inspection and quarantine bureaus, etc.
Founded in 2016, Rocgene (Beijing) Technology Co., Ltd. (hereinafter referred to as Rocgene) is a bio-tech company founded by scientists and business people and driven by core technologies. Rocgene is committed to transforming new technologies in the field of life science research into clinically relevant medical research products, and developing scientific research and molecular diagnostic products with independent intellectual property rights.
Rocgene has obtained the qualifications of "National High-tech Enterprise" and "Zhongguancun High-tech Enterprise", declared 6 invention patents, 6 utility model patents, and obtained 16 software copyright certificates. It has a clean production area of more than 10,000 square meters in Xuzhou High-tech Zone between. Rocgene adheres to the courage of self-transcendence and the arrogance of 90,000 miles, and is determined to become an industry leader with forward-looking vision.